Nxera Pharma Co., Ltd.(4565) News

Nxera Pharma shares continue to rise on milestone achievement in drug discovery partnership with AbbVie

Nxera Pharma hits third milestone in AbbVie neuroscience collaboration

Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases

Notice of Issuance of New Shares in Connection with J-ESOP and RSUs, and Determination of Payment Amount and Other Matters for Prior RSU Awards

Nxera Pharma’s QUVIVIQ (daridorexant) 25mg and 50mg Receives Approval in Taiwan for the Treatment of Insomnia

Nxera Pharma’s Partner Neurocrine Biosciences Doses First Patient in Phase 2 Trial of NBI-1117570 for Adults with Schizophrenia

Nxera Pharma Hits New Year-to-Date High on Second Development Milestone Achievement in Eli Lilly Partnership

Nxera Pharma Achieves Second Development Milestone in Collaboration with Eli Lilly Targeting Metabolic Diseases

Active Stocks (Close): SAMCO, REFINVERSE Group, Nxera Pharma and others

Nxera Pharma surges again, briefly hitting daily limit as partner Centessa to be acquired by Eli Lilly

Nxera Pharma’s Partner Centessa Pharmaceuticals to be Acquired by Lilly

Notice Concerning New Management Structure

Nxera Pharma to Receive $3 Million Milestone Payment from Centessa Pharmaceuticals

Nxera Pharma Submits Marketing Authorization Application for Daridorexant in South Korea

Nxera Pharma Proposes Changes to its Board of Directors

Nxera Pharma to Record Extraordinary Loss on Impairment of Shares of Consolidated Subsidiary (Non-Consolidated)

Nxera Pharma, Last Fiscal Year's Net Income Loss Widens, Current period performance is undisclosed.

Nxera Pharma Operational Highlights and Consolidated Results for the Fourth Quarter and Full Year 2025

Variance of Consolidated Results Between the Year Ended 31 December 2025 and the Previous Year

Notice Concerning Reduction of Executive Compensation